AstraZeneca is looking for partnerships in neurosciences
AstraZeneca is a global, innovation-driven, integrated biopharmaceutical company. They discover, develop, manufacture and market prescription medicines for six important areas of healthcare, which include some of the world’s most serious illnesses: cancer, cardiovascular, gastrointestinal, infection, neuroscience, and respiratory and inflammation.
Their research has breadth, and depth and focuses on disease areas where AstraZeneca and their partners can make the most meaningful impact on patients’ lives. Innovative Medicine’s Units (iMeds) are responsible for driving research from discovery to early development in their core therapeutic areas, while New Opportunities group looks for strategic areas of focus outside their core disease areas.
Neuroscience is an area with huge unmet medical need. Their virtualised Neuroscience model is pioneering new ways to share cost, risk and reward with research partners to deliver effective treatments for CNS disorders and pain. They are working with a network of external partners to progress new projects flexibly and quickly from discovery through early development. They are interested in small and large molecule research to discover and develop new treatments in neurology, psychiatry and pain.